^
Association details:
| Biomarker: | MGMT unmethylation |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | olaptesed pegol (NOX-A12) (CXCL12 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
NOXXON ANNOUNCES COMPLETION OF 6-MONTH THERAPY FOR LOW-DOSE COHORT IN PHASE 1/2 BRAIN CANCER STUDY OF NOX-A12 PLUS RADIOTHERAPY
Published date:
10/28/2020
Excerpt:
The study investigates three dose regimens of NOX-A12 (200, 400 and 600 mg/week), each combined with external beam radiotherapy in newly diagnosed MGMT1 promoter unmethylated glioblastoma patients...Tumor volume reductions were observed in two of three patients during the six-month treatment, and inthe third patient in the period after a second surgery following continued NOX-A12 treatment.
